A recombinant humanized monoclonal IL-6R antagonist (tocilizumab) has been approved as an anti-inflammatory drug for inflammatory diseases such as rheumatoid arthritis, Castleman’s disease, and systemic juvenile idiopathic arthritis. The gene discussed is IL6R; the disease is rheumatoid arthritis.